Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2022-01-10 00:00:00 ET · period of report 2022-01-06 · accession 0001209191-22-002748 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-10 | 2022-01-06 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +9,527 | 62.4K | +18% | — |
| D | 2022-01-10 | 2022-01-06 | ACAD | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $23.05 | -3,718 | 58.7K | -6% | -$85.7K |
| D | 2022-01-10 | 2022-01-06 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | $0.00 | -9,527 | 19.1K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-06 | M | A | 9,527 | — | 62,434 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 1 share of the Issuer's common stock acquired by the reporting person on November 15, 2021 pursuant to an employee stock purchase program. |
| 2 | Common | Common Stock | 2022-01-06 | S | D | 3,718 | $23.05 | 58,716 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2022-01-06 | M | D | 9,527 | $0.00 | 19,056 | D | — · — to — | 9,527 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F4) The restricted stock units vest in four equal annual installments beginning January 6, 2021. |